The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients: Final 5-year follow-up of the Endeavor Japan study

摘要

Introduction: The Endeavor stent (Medtronic Cardio-Vascular, Santa Rosa, CA, USA) combines a biocompatible phosphorylcholine polymer with a new molecular entity, zotarolimus, and has shown consistent safety and efficacy benefits across a broad range of lesion subsets and patient populations [ 1-5].The Endeavor Japan Study was a single-arm, multicenter, confirmatory, clinical trial using data from the ENDEAVOR II trial as a historical control [1]. Endeavor Japan was prospectively designed to mimic the inclusion/exclusion criteria, procedures, event definitions, and angiographic analyses, including the use of identical core laboratories from ENDEAVOR II [1]. These design features were selected specifically to enhance the poolability, statistical comparisons, and interpretability of the Endeavor stent performance in a Japanese population.